Clinically isolated syndrome: A protected zone for trials of new therapies?

Multiple Sclerosis

Volumn 16, Issue 6, 2010, Pages 754-755

  Hutchinson, Michael ^a   Zajicek, John ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO;

CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICALLY ISOLATED SYNDROME; DEMYELINATING DISEASE; DRUG EFFICACY; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; CLINICAL TRIAL (TOPIC); DEMYELINATING DISEASES;

CLINICAL TRIALS AS TOPIC; DEMYELINATING DISEASES; HUMANS;

EID: 77953732643     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510366015     Document Type: Note

References (12)

1. Gilmore CP, Cottrell DA, Scolding NJ, Wingerchuk DM, Weinshenker BG, Boggild M. A window of opportunity for no treatment in early MS? Mult Scler 2010 ; [Epub ahead of print].
2. Frohman EM, Havrdova E., Lublin F., et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006 ; 63: 614-619.
3. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 2009 ; 15: 1175-1182.
4. Pittock SJ Uncertain BENEFIT of early interferon beta-1b treatment. Lancet Neurol 2009 ; 8: 970-971 (editorial).
5. Jacobs L., Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Eng J Med 2000 ; 343: 898-904.
6. Comi G., Fillippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to clinically definite multiple sclerosis: a randomized study. Lancet 2001 ; 357: 1576-1582.
7. Kappos L., Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67: 1242-1249.
8. Comi G., Martinelli V., Rodegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009 ; 374: 1503-1511.
9. Polman CH, Reingold SC, Edan GE, et al. Diagnostic criteria for multiple sclerosis: (2005) Revisions to the McDonald Criteria. Ann Neurol 2005 ; 58: 840-846.
10. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002 ; 52: 47-53.
11. Tintore M., Rovira A., Rio J., et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003 ; 60: 27-30.
12. Miller D., Barkhof F., Montalban X., Thompson A., Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005 ; 4: 281-288.